from humans A61K38/22Hormones A61K38/30Insulin-like growth factors, i.e
WO2019239340A1 - Reduced glutathione in a highly soluble, amorphous solid form, and process for the preparation thereof - Google Patents Reduced glutathione in a highly soluble, amorphous solid form, and process for the preparation thereof Download PDF Info Publication number WO2019239340A1 WO2019239340A1 PCT/IB2019/054906 IB2019054906W WO2019239340A1 WO 2019239340 A1 WO2019239340 A1 WO 2019239340A1 IB 2019054906 W IB2019054906 W IB 2019054906W WO 2019239340 A1 WO2019239340 A1 WO 2019239340A1 Authority WO WIPO (PCT) Prior art keywords glutathione reduced glutathione sodium salt product aqueous solution Prior art date Legal status (The legal status is an assumption and is not a legal conclusion
Chandra, N
There is no accumulation concern with either formulation at standard injectable doses
placebo on CV outcomes, which showed that dulaglutide was associated with a small yet significant reduction in ED risk (HR 0.92, 95% CI 0.850.99, p = 0.021) in 3725 patients with T2D and class I obesity
Kim HJ, Khalimonchuk O, Smith PM, Winge DR (2012) Structure, function, and assembly of heme centers in mitochondrial respiratory complexes
